Skip to main content

Select Drug Profiles

Original Research
Evaluating Adherence to Dilated Eye Examination Recommendations Among Patients with Diabetes, Combined with Patient and Provider Perspectives
Maxine D. Fisher, PhD, Yamina Rajput, MS, Tao Gu, PhD, Joseph R. Singer, MD, Amanda R. Marshall, BS, Seonyoung Ryu, PharmD, John Barron, PharmD, Catherine MacLean, MD, PhD, Josephine N. Tran, PharmD, MS, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACE, FTOS
Stakeholder Perspective
Provider and Payer Collaboration Needed to Ensure Adherence to Recommended Eye Examinations in Patients with Diabetes
by Quang T. Nguyen, DO, FACE, FTOS, Raymond A. Plodkowski, MD
Read More
Original Research
Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia
Marie-Hélène Lafeuille, MA, Christian Frois, PhD, Michel Cloutier, PhD, Mei Sheng Duh, MPH, ScD, Patrick Lefebvre, MA, Jacqueline Pesa, PhD, MPH, Zoe Clancy, PharmD, John Fastenau, RPh, MPH, Mike Durkin, MSc
Stakeholder Perspective
Patient Characteristics, Adherence, and a Metric of Organizational Performance in Behavioral Health
by Michael F. Murphy, MD, PhD
Read More
Perspectives
“Learning from Yellowstone”: Commencement Address to Philadelphia University Physician Assistants Graduating Class
David B. Nash, MD, MBA
Read More
Practice Management
Examining the Value of Subsidies of Health Plans and Cost-Sharing for Prescription Drugs in the Health Insurance Marketplace
Surachat Ngorsuraches, PhD, Jane R. Mort, PharmD
Stakeholder Perspective
Health Plan Subsidies, Prescription Drugs, and Cost
by Byron C. Scott, MD, MBA
Read More
Payers' Guide, FDA Approvals
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Read More
Perspectives
Eye of the Consolidation Storm
David B. Nash, MD, MBA
Read More
Practice Management
Revealed Opportunism: How Physicians “Game” Prior Authorization Protocols Until They Are Rescinded
Natan R. Kahan, RPh, MHA, PhD, Dan-Andrei Waitman, MD, MPH, David P. Chinitz, PhD
Stakeholder Perspective
A Matter of Trust
by Albert Tzeel, MD, MHSA, CPE, FAAPL
Read More
Original Research
Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population
John Barron, PharmD, Yiqiong Xie, PhD, Sze-jung Wu, PhD, Jeff White, PharmD, Joseph R. Singer, MD, Bernard Tulsi, MSc, Alan Rosenberg, MD
Stakeholder Perspective
Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection
by Jack E. Fincham, PhD, RPh
Read More
Original Research
Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer
Daniel B. Ng, PharmD, MBA, Melissa McCart, PharmD, MS, Christopher Klein, BS, Chelsey Campbell, PharmD, MBA, Robert Schoenhaus, PharmD, Todd Berner, MD
Stakeholder Perspective
Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment
by Kelly Huang, PhD
Read More
Practice Management
Employer Perspectives on a Specialty Drug Step-Therapy Program Evaluation
Matthew Harman, PharmD, MPH, F. Randy Vogenberg, PhD, FASHP
Read More
Page 105 of 244
Results 1041 - 1050 of 2434